Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914522 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,351
- Enrollment target
NCT02914522 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,351 participants.
The verdict
NCT02914522, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,351 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).
Interventions
- DRUG Filgotinib
- DRUG PTM filgotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,351 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914522
The ClinicalTrials.gov registry entry for NCT02914522 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Filgotinib is the first listed.
NCT02914522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02914522 about?
NCT02914522 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis". The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced. Participants who complete the study, or met protocol s...
What is the current status of trial NCT02914522?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,351 participants. The study started on 2016-11-14. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT02914522?
The interventions under investigation include: Filgotinib (DRUG), PTM filgotinib (DRUG).
Who is sponsoring clinical trial NCT02914522?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.